Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
SAN DIEGO, Aug. 13, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Nos. 8,466,183 and 8,481,573 which cover compounds including the Company’s proprietary selective sphingosine-1-phosphate 1 receptor (S1P1R) modulator, RPC1063. These composition of matter patents will have an initial patent term extending to May 2029.
Help employers find you! Check out all the jobs and post your resume.
